ArticleBiologics : targets & therapy2011
A combined Phase I and II open-label study on the immunomodulatory effects of seaweed extract nutrient complex.
Article in Biologics : targets & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Effects of fucoidan supplementation on inflammatory and immune response after high-intensity exercise.Journal of the International Society of Sports Nutrition · 2023Trial
- Novel Technologies for Seaweed Polysaccharides Extraction and Their Use in Food with Therapeutically Applications-A Review.Foods (Basel, Switzerland) · 2022Review
- Phytochemical and Potential Properties of Seaweeds and Their Recent Applications: A Review.Marine drugs · 2022Review
- Application of Fucoidan in Caco-2 Model Establishment.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Soluble Polysaccharide Derived fromMarine drugs · 2021Article
- An Overview to the Health Benefits of Seaweeds Consumption.Marine drugs · 2021Review
- A Pragmatic Approach to Immunity & Respiratory Viral Infections.Integrative medicine (Encinitas, Calif.) · 2020Article
- Seaweed's Bioactive Candidate Compounds to Food Industry and Global Food Security.Life (Basel, Switzerland) · 2020Review
- Marine Polysaccharides in Pharmaceutical Applications: Fucoidan and Chitosan as Key Players in the Drug Delivery Match Field.Marine drugs · 2019Review
- Fucoidan attenuates radioiodine-induced salivary gland dysfunction in mice.BMC oral health · 2019Article
- Effects of scavenger receptors-1 class A stimulation on macrophage morphology and highly modified advanced glycation end product-protein phagocytosis.Scientific reports · 2018Article
- Marine polysaccharides: therapeutic efficacy and biomedical applications.Archives of pharmacal research · 2017Review
- Fucoidans in Nanomedicine.Marine drugs · 2016Review
- Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial.Biologics : targets & therapy · 2016Article
- Effects of Laminaria japonica polysaccharides on airway inflammation of lungs in an asthma mouse model.Multidisciplinary respiratory medicine · 2015Article
- Fucoidan as a marine anticancer agent in preclinical development.Marine drugs · 2014Review
- Antioxidant, antiproliferative, and antiangiogenesis effects of polyphenol-rich seaweed (Sargassum muticum).BioMed research international · 2013Article
- Therapies from fucoidan; multifunctional marine polymers.Marine drugs · 2011Review
- Changes in rats' breast tumor ultrastructure and immune and messenger RNA responses caused by dietary Seaweed (Journal of microscopy and ultrastructureArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIsolated fucoidans from brown marine algae have been shown to have a range of immune-modulating effects. This exploratory study aimed to determine whether a seaweed nutrient complex containing a blend of extracts from three different species of brown algae plus nutrients is safe to administer and has biological potential as an immune modulator. The study was undertaken as an open-label combined Phase I and II study.
methodsParticipants (n = 10) were randomized to receive the study medication at either a 100 mg (n = 5) or 1000 mg (n = 5) dose over 4 weeks. The primary outcome measurement was in vivo changes in lymphocyte subsets. The secondary outcome measures were ex vivo changes in T-lymphocyte (CD4 and CD8) activation, phagocytosis of granulocytes and monocytes, T helper 1/T helper 2 cytokines, and serum oxygen radical absorbance capacity.
resultsThe preparation was found to be safe over the 4 weeks at both doses tested. There were no clinically relevant changes to blood measurements of hemopoietic, hepatic, or renal function. Immunomodulatory measurements showed no dose response between the two doses. The combined results from the two doses demonstrated a significant increase in cytotoxic T cell numbers and phagocytic capacity in monocytes, and a significant decrease in levels of the inflammatory cytokine interleukin 6. A separate analysis of the 100 mg dose (n = 5) alone showed a significant linear component over time (P < 0.05) for phagocytosis by both granulocytes and monocytes.
conclusionThe seaweed nutrient complex was safe to use when taken orally over 4 weeks. The preparation was demonstrated to have potential as an immune modulator, and this bioactivity deserves further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.